San Francisco, CA, United States of America

Daniel D Long

USPTO Granted Patents = 104 (Patent Applications = 8)

CIPO Patents = 10 (Patent Applications = 12)

EPO Patents = 27 (Patent Applications = 25)

Average Co-Inventor Count = 4.3

ph-index = 14

Forward Citations = 667(Granted Patents)

Forward Citations (Not Self Cited) = 346(Oct 12, 2025)

Inventors with similar research interests:

Location History:

San Franicsco, CA (US) (2010)
South San Francisco, CA (US) (2020 - 2021)
San Francisco, CA (US) (2005 - 2024)

Company Filing History:

Theravance Biopharma R&d Ip, LLC

patents

2 out of 2

Praxis Bioresearch, LLC

patents

Years Active: 2005-2025

Loading Chart...

104 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12398135 - Dimethyl amino azetidine amides as JAK inhibitors (2025-08-26),

2. 11919836 - Prodrugs of fencamfamine (2024-03-05),

3. 11845747 - Ester and carbonate pyrimidine compounds as JAK kinase inhibitors (2023-12-19),

4. 11713315 - 5 to 7 membered heterocyclic amides as JAK inhibitors (2023-08-01),

5. 11634419 - Dimethyl amino azetidine amides as JAK inhibitors (2023-04-25),

6. 11608354 - Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease (2023-03-21),

7. 11548887 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2023-01-10),

8. 11155549 - Ester and carbonate pyrimidine compounds as JAK kinase inhibitors (2021-10-26),

9. 10961267 - Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease (2021-03-30),

10. 10947229 - Dimethyl amino azetidine amides as JAK inhibitors (2021-03-16),

11. 10836763 - 5 to 7 membered heterocyclic amides as JAK inhibitors (2020-11-17),

12. 10745405 - Glucuronide prodrugs of Janus kinase inhibitors (2020-08-18),

13. 10745394 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2020-08-18),

14. 10662146 - Prodrugs of fencamfamine (2020-05-26),

15. 10472366 - Glucuronide prodrugs of tofacitinib (2019-11-12),

Title: **Daniel D Long: Innovator in Pharmaceutical Patent Development**

Introduction

Daniel D Long, based in San Francisco, California, is a prolific inventor with an impressive portfolio of 103 patents to his name. His innovative work primarily focuses on the development of pharmaceutical compositions and compounds, contributing significantly to therapeutic advancements in medicine.

Latest Patents

Among his latest patents, the "Prodrugs of Fencamfamine" stands out, which discloses pharmaceutical compositions incorporating fencamfamine or related prodrug derivatives aimed at targeted therapeutic applications. His other notable invention, the "Ester and Carbonate Pyrimidine Compounds as JAK Kinase Inhibitors," provides compounds that act as inhibitors of Janus kinases, releasing active metabolites in vivo and offering promising treatments for inflammatory skin diseases and other conditions.

Career Highlights

Daniel has contributed his expertise to prominent firms, including Theravance and Theravance Biopharma R&D IP, LLC. His tenure at these companies reflects his dedication to advancing pharmaceutical research and development.

Collaborations

Throughout his career, Long has worked alongside talented professionals in the field, including Daniel Marquess and Paul Ross Fatheree. These collaborations highlight the importance of teamwork in driving innovation and successfully bringing new ideas to fruition.

Conclusion

Daniel D Long's innovative spirit and extensive patent portfolio underscore his significant contributions to the pharmaceutical industry. His latest work has the potential to impact therapeutic applications, showing the vital role inventors play in addressing healthcare challenges.

This text is generated by artificial intelligence and may not be accurate.